(NewsDirect)
Race Oncology Ltd(ASX:RAC) executive director Dr Pete Smith speaks with Proactive soonafter announcing the company has initiated the toxicology and safetypharmacology studies required to support human clinical trials of itsflagship bisantrene formulation for peripheral infusion, RC220. Thecompany has signed contracts with Attentive Science (USA) and AgilexBiolabs (Australia) to complete a package of Good Laboratory Practice(GLP) toxicology and safety pharmacology studies. Set to commenceimmediately, final reporting is expected mid next year.
Smith said: “Thesecritical studies represent a significant milestone for Race and theclinical and commercial development of RC220 by establishingbisantrene’s known safety profile in its new formulation.
“Attentive Science and Agilex Biolabs areimpressive and complementary organisations, each specialising in thedifferent aspects of the required work. We are confident that inexecuting these studies they will meet our high expectations in termsof time, cost and quality.”
ContactDetails
Proactive Investors
GreggCastano
+1 203-762-5649
Copyright (c) 2023 TheNewswire - All rights reserved.